The Washington University trial comes as part of a larger platform study, which hopes to understand whether the disease can ...

While the world waits an effective coronavirus vaccine, Eli Lilly has started late-stage human testing an antibody drug as an alternative way to prevent viral transmission in high-risk locations.

The US government said it will buy 300,000 doses of Eli Lilly’s COVID-19 therapy ... “Our goal is to ensure that Lilly antibody treatments are available to patients who need them, no matter ...

The first participants in an international clinical trial aimed at preventing Alzheimer’s disease in young adults at high ...

It’s been a rough month for several clinical amyotrophic lateral sclerosis (ALS) candidates, but that’s not stopping Eli Lilly from pursuing new drugs of its own for the devastating ...

Eli Lilly is making a play for the idiopathic pulmonary ... gives Lilly global rights to the anti-WISP1 antibody MTX-463. Researchers have linked WISP1 to fibrosis progression, leading Mediar ...

Eli Lilly's operational performance is strong ... And finally, Emgality, which serves as a humanized monoclonal antibody for those who suffer from migraines, saw a rise in revenue from $168.5 ...